Artículos por temáticas

LRRK2 and the fragile synapse: a molecular prelude to Parkinson's disease?

Masotti B, Tombesi G, Parisiadou L, Greggio E.

Biochem J. 2025 Oct 28;482(21):BCJ20253351. doi: 10.1042/BCJ20253351.

Gender Is the Main Predictor of Wearing-Off and Dyskinesia in Levodopa-Naïve Patients with Parkinson's Disease

Pellecchia MT, Picillo M, Russillo MC, Amboni M, Arabia G, Avanzino L, Canesi M, Catania A, Ceravolo R, Cicero CE, Cilia R, Colangelo I, Dati G, De Micco R, De Rosa A, Di Fonzo A, Eleopra R, Fetoni V,

Mov Disord Clin Pract. 2025 Nov;12(11):1774-1783. doi: 10.1002/mdc3.70143. Epub 2025 May 29.

Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson's disease

Zhang Y, Mo C, Ai P, He X, Xiao Q, Yang X.

Gut Microbes. 2025 Dec;17(1):2454937. doi: 10.1080/19490976.2025.2454937. Epub 2025 Jan 28.

Advanced therapy in advanced Parkinson's disease: money's too tight to mention

Jost WH.

J Neural Transm (Vienna). 2025 Nov;132(11):1627-1628. doi: 10.1007/s00702-024-02871-2. Epub 2024 Dec 21.

Berberine's paradox in Neurodegeneration: Therapeutic promise and safety challenges in Parkinson's disease

Alshahrani SM, Al-Kuraishy HM, Al-Gareeb AI, Albuhadily AK, Fawzy MN, Kadasah SF, Alruwaili M, Papadakis M, Alexiou A, El-Saber Batiha G.

Neuropharmacology. 2025 Nov 1;278:110555. doi: 10.1016/j.neuropharm.2025.110555. Epub 2025 Jun 6.

Nrf2-Keap1 Pathway and NLRP3 Inflammasome in Parkinson's Disease: Mechanistic Crosstalk and Therapeutic Implications

Jain R, Vora L, Nathiya D, Khatri DK.

Mol Neurobiol. 2025 Nov 20;63(1):91. doi: 10.1007/s12035-025-05389-0.

The efficacy and safety of acupuncture for Parkinson's disease insomnia: a systematic review and meta-analysis

Gu Y, Liang Y, Han H, Yin H, Zheng Z.

Front Neurol. 2025 Nov 3;16:1697481. doi: 10.3389/fneur.2025.1697481. eCollection 2025.

The Effect of Metformin on Astrocytes in Parkinson's Disease: Challenges and Opportunities

Al-Kuraishy HM, Sulaiman GM, Saad HM, Mohammed HA, Abomughaid MM, Al-Gareeb AI, Albuhadily AK.

Mol Neurobiol. 2025 Nov;62(11):15055-15069. doi: 10.1007/s12035-025-05098-8. Epub 2025 Jun 4.

Non-coding RNAs in Parkinson's Disease: Pathogenesis, Exosomes, and Therapeutic Horizons

Rezaei N, Zivari M, Kazemi M, Alani B, Noureddini M, Rafiyan M, Bahrami A, Yazdani MS, Eshraghi R, Mazoochi T, Mirzaei H.

Cell Mol Neurobiol. 2025 Nov 26. doi: 10.1007/s10571-025-01618-1. Online ahead of print.

The microbiome: what a neurologist needs to know

Dehghanizai AB, Stewart CJ, Thomas RH.

Pract Neurol. 2025 Nov 13;25(6):527-534. doi: 10.1136/pn-2024-004400.

In Memoriam: Leonard Mindich 1936-2024

Gottlieb P.

Viruses. 2025 Oct 31;17(11):1451. doi: 10.3390/v17111451.

Dual role of microglia in neuroinflammation and neurodegenerative diseases

Ajoolabady A, Kim B, Abdulkhaliq AA, Ren J, Bahijri S, Tuomilehto J, Borai A, Khan J, Pratico D.

Neurobiol Dis. 2025 Nov;216:107133. doi: 10.1016/j.nbd.2025.107133. Epub 2025 Oct 4.

Immunosenescence in aging and neurodegenerative diseases: evidence, key hallmarks, and therapeutic implications

Chen Z, Mao Z, Tang W, Shi Y, Liu J, You Y.

Transl Neurodegener. 2025 Nov 27;14(1):60. doi: 10.1186/s40035-025-00517-1.

Epigenetic Mediating Mechanisms in Parkinson's Disease: The Impact of Educational Attainment on SETD1A Expression

Yin KF, Gu XJ, Yu JM, Su WM, Yang WJ, Duan QQ, He SY, Shen C, Lu SJ, Chi LY, Wang Y, Cao B, Chen YP.

Mov Disord. 2025 Nov;40(11):2431-2444. doi: 10.1002/mds.70010. Epub 2025 Aug 19.

Deubiquitinating enzymes in parkinson's disease: molecular mechanisms and therapeutic potential

Wu Y, Deng Y, Ai Q, Li Y, Qin F, Hammad M, Meng Z, Xu X, Wei J, Yu H, Liang G, Zhao X.

Mol Med. 2025 Nov 7;31(1):329. doi: 10.1186/s10020-025-01389-x.